CNBX Pharmaceuticals Inc. (CNBX)

Market Cap	381.12K
Revenue (ttm)	534,019
Net Income (ttm)	-920,479
Shares Out	31.11M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	218,244
Open	0.0110
Previous Close	0.0125
Day's Range	0.0100 - 0.0146
52-Week Range	0.0100 - 0.0500
Beta	0.87
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About CNBX

CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast canc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: CNBX

Financial Performance

In 2023, CNBX's revenue was $410,165, an increase of 1269.13% compared to the previous year's $29,958. Losses were -$3.71 million, -1.56% less than in 2022.